 | |
Subscribe to our Email List
| |
In November 2007, Verona Pharma announced that it has acquired significant know-how from a leading North American biotechnology company for a potential anti-tussive drug. This potential drug treatment will work to suppress the generation of a cough signal at the nerve endings in the lungs. The Company is currently undergoing studies of a selected compound with the intention of commencing preclinical safety evaluation studies in early 2010.
The programme will address the problem that while unexplained cough is one of the most common medical complaints, there remains no truly effective treatment for what can be a very debilitating condition. Anti-cough treatments currently available are either morphine-based, or derivatives of morphine. The side effects of morphine, including its addictive effects, limit its use.
| | |
